Klebsiella pneumoniae carbapenemase variants: the new threat to global public health
Clinical Microbiology Reviews · 20.12.2023 · 36 (4)
DOI: 10.1128/cmr.00008-23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 20.12.2023. Verfasst von Li Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Public Health. Die Arbeit wurde bisher 227-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China (NSFC), China Antimicrobial Surveillance Network.
Abstract (Originalsprache)
Klebsiella pneumoniae carbapenemase (KPC) variants, which refer to the substitution, insertion, or deletion of amino acid sequence compared to wild bla KPC type, have reduced utility of ceftazidime-avibactam (CZA), a pioneer antimicrobial agent in treating carbapenem-resistant Enterobacterales infections. So far, more than 150 bla KPC variants have been reported worldwide, and most of the new variants were discovered in the past 3 years, which calls for public alarm. The KPC variant protein enhances the affinity to ceftazidime and weakens the affinity to avibactam by changing the KPC structure, thereby mediating bacterial resistance to CZA. At present, there are still no guidelines or expert consensus to make recommendations for the diagnosis and treatment of infections caused by KPC variants. In addition, meropenem-vaborbactam, imipenem-relebactam, and other new β-lactam-β-lactamase inhibitor combinations have little discussion on KPC variants. This review aims to discuss the clinical characteristics, risk factors, epidemiological characteristics, antimicrobial susceptibility profiles, methods for detecting bla KPC variants, treatment options, and future perspectives of bla KPC variants worldwide to alert this new great public health threat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
- Hangzhou Matridx Biotechnology Co., Ltd., Hangzhou, Zhejiang, China.
ORCID-Profile: Li Ding, Siquan Shen, Yan Guo, Fupin Hu
Förderung
- National Natural Science Foundation of China (NSFC)
- China Antimicrobial Surveillance Network
Zitieren
APA
Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., Guo, Y., & Hu, F. (2023). Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clinical Microbiology Reviews, 36(4). https://doi.org/10.1128/cmr.00008-23
Vancouver
Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clinical Microbiology Reviews. 2023;36(4). doi:10.1128/cmr.00008-23
BibTeX
@article{Ding2023,
author = {Ding, Li and Shen, Siquan and Chen, Jing and Tian, Zhen and Shi, Qingyu and Han, Renru and Guo, Yan and Hu, Fupin},
title = {Klebsiella pneumoniae carbapenemase variants: the new threat to global public health},
journal = {Clinical Microbiology Reviews},
year = {2023},
volume = {36},
number = {4},
doi = {10.1128/cmr.00008-23}
}
EUVIMED